Schedule 13D ownership disclosure

Vera Therapeutics Inc

Class A Common Stock, $0.001 par value · CUSIP: 92337R101

Event date: 2025-12-10

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Sofinnova Venture Partners X, L.P. ("SVP X")Reported CIK 0001680200

    Shares: 2,793,987.00 · Class: 3.9%

  • Sofinnova Management X, L.P. ("SM X LP")

    Shares: 2,793,987.00 · Class: 3.9%

  • Sofinnova Management X-A, L.L.C. ("SM X LLC")

    Shares: 2,793,987.00 · Class: 3.9%

  • Dr. James I. Healy ("Healy")

    Shares: 2,793,987.00 · Class: 3.9%

  • Dr. Maha Katabi ("Katabi")

    Shares: 2,847,837.00 · Class: 4.0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-26-023756
Form type
SCHEDULE 13D/A
Filer
Sofinnova Venture Partners X, L.P.
CIK
CIK 1680200
Filed
Mar 05, 2026
Reporting period
Dec 10, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub